Abstracts tagged "Comorbidity"

Abstract Number: 2013 • 2019 ACR/ARP Annual Meeting
Increased Accumulation of Malondialdehyde-Acetaldehyde Modified HDL in Macrophage Without Decreased Cholesterol Efflux
Kevin Real¹, Michael Duryee ¹, Patrick Opperman ¹, Evan Ryan ¹, Logan Duryee ¹, James O'Dell ², Ted Mikuls ², Daniel Anderson ¹ and Geoffrey Thiele ², ¹University of Nebraska Medical Center, Omaha, NE, ²VA Nebraska-Western IA Health Care System & University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Patients with rheumatoid arthritis (RA) are approximately two-fold more likely to develop cardiovascular disease (CVD). Prior reports have suggested that “dysfunctional” HDL may explain…
Abstract Number: 2070 • 2019 ACR/ARP Annual Meeting
Co-morbidities in Patients with OA and RA: Results from a Large US Rheumatic Disease Registry
Sofia Pedro¹, Rebecca Schumacher ¹, Alyssa Dominique ², Yomei Shaw ¹, Kristin Wipfler ¹ and Kaleb Michaud ³, ¹FORWARD, The National Databank for Rheumatic Diseases, Wichita, KS, ²Bristol-Myers Squibb, Princeton, NJ, ³FORWARD, The National Databank for Rheumatic Diseases and University of Nebraska Medical Center, Wichita, KS
Background/Purpose: The burden of co-morbid conditions can impact the overall quality of life in patients with RA and OA. However, the presence of common co-morbidities…
Abstract Number: 2295 • 2019 ACR/ARP Annual Meeting
Burden of Systemic Lupus Erythematosus Among Korean Women in Childbearing Years Based on the National Health Insurance Service Data
Min Kyung Chung ¹, Jin Su Park ², Hyun Sun Lim ², Chan Hee Lee ² and Jisoo Lee¹, ¹Division of Rheumatology, Department of Internal Medicine, Ewha Womans University School of Medicine, Seoul, Republic of Korea, ²Division of Rheumatology, Department of Internal Medicine, National Health Insurance Service Ilsan Hospital, Goyang, Republic of Korea
Background/Purpose: Most women with systemic lupus erythematosus (SLE) are diagnosed with the disease in their reproductive ages, but the burden of SLE among women in…
Abstract Number: 2313 • 2019 ACR/ARP Annual Meeting
Patients with Rheumatoid Arthritis Have a Higher Risk of Bipolar Disorder: A Systematic Review and Meta-analysis
Patompong Ungprasert¹, Nipith Charoenngam ² and Ben Ponvilawan ², ¹Cleveland Clinic, Cleveland, OH, Bangkok, Thailand, ²Mahidol University, Bangkok, Thailand
Background/Purpose: Patients with chronic autoimmune diseases may have a higher risk of psychiatric illness as a result of chronic neuro-inflammation and immune dysregulation. The current…
Abstract Number: 2332 • 2019 ACR/ARP Annual Meeting
Cardiovascular Risk Factors in Rheumatoid Arthritis: Prevalence, Comparison of Risk Calculators and Subclinical Atherosclerosis in Indian Patients
Hafis Muhammed¹, Durga P Misra ¹, Sujata Ganguly ¹, Sarit Sekhar Pattanaik ¹, Saurabh Chaturvedi ¹, Harshit Singh ¹, Mohit K Rai ¹, Anamika Anuja ¹, Namita Mohindra ¹, Neeraj Jain ¹, Sudeep Kumar ¹ and Vikas Agarwal ¹, ¹SGPGI, Lucknow, Uttar Pradesh, India
Background/Purpose: Rheumatoid arthritis(RA) patients have increased cardiovascular(CV) risk with no data on CV risk scores in Indian patients.The primary objective was to study prevalence of…
Abstract Number: 2465 • 2019 ACR/ARP Annual Meeting
Reliability and Validity of the Self‐Administered Comorbidity Questionnaire in Psoriatic Arthritis
Didem Erdem¹, Halise Hande Gezer ², Sevtap Acer Kasman ¹ and Mehmet Tuncay Duruoz ¹, ¹Marmara University School of Medicine, PMR Department, Rheumatology Division, İstanbul, Turkey, ²Marmara University School of Medicine, PMR Department, Rheumatology Division, İstanbul, Istanbul, Turkey
Background/Purpose: The Self‐Administered Comorbidity Questionnaire (SCQ) is a self-report questionnaire. It assesses 13 common medical conditions and the impact of comorbidities on functional status (1).…
Abstract Number: 2494 • 2019 ACR/ARP Annual Meeting
Comparison of Comorbidity in Spondyloarthritis: Influence on Inflammatory Activity in Patients with Psoriatic Arthritis
Luis Gomez-Lechon¹, Maria Elisa Acosta ¹, Guadalupe Manzano Canabal ¹, Olga Compan ¹, Cristina Hidalgo ², Olga Martinez ¹, Ana Turrión ¹, Javier del Pino ¹ and Carlos Montilla ¹, ¹Hospital Clínico Universitario de Salamanca, Salamanca, Spain, ²Hospital Clínico Universitario de Salamanca, Salamanca, Castilla y Leon, Spain
Background/Purpose: Psoriatic arthritis (PsA) is a heterogeneous disease that is included in the group of spondyloarthritis. Although PsA has its own clinical characteristics, it has…
Abstract Number: 2890 • 2019 ACR/ARP Annual Meeting
The Effect of Rheumatoid Arthritis and Biologics on the Acquisition of Subsequent Diseases and Adverse Events: A Matched Longitudinal Population Study
Mark Tatangelo¹, George Tomlinson ², Edward Keystone ³, Michael Paterson ⁴, Nick Bansback ⁵ and Claire Bombardier ⁶, ¹University of Toronto, Toronto, Canada, ²University of Toronto, Toronto, ON, Canada, ³Mount Sinai Hospital and University of Toronto, Toronto, ON, Canada, ⁴Institute for Clinical Evaluative Sciences, Toronto, Canada, ⁵University of British Columbia, Vancouver, Canada, ⁶Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada
Background/Purpose: The direct and indirect effects of rheumatoid arthritis (RA) are difficult to measure in observational studies because: (1) The inflammatory effects of RA are…
Abstract Number: 332 • 2018 ACR/ARHP Annual Meeting
Components of Impaired Physical Function and Disability in a Non-Rheumatic Population. Normative Values of the Health Assessment Questionnaire Disability Index
C Alejandro Arce-Salinas¹, H FABRICIO ESPINOSA-ORTEGA² and Olivia Enriquez-Antonio³, ¹INTERNAL MEDICINE, Hospital Central Sur PEMEX, MEXICO, Mexico, ²Rheumatology Department, Karolinska Universitetssjukhuset, Stockolm, Sweden, ³Internal Medicine, Hospital Central Sur PEMEX, mexico, Mexico
Background/Purpose: HAQ-Di is broadly used to measure disability in RA, its assessment might influence taking decision process. However, it cannot differentiate disability related to arthritis,…
Abstract Number: 2768 • 2018 ACR/ARHP Annual Meeting
Comorbidity Accrual and Mortality in an Inception Cohort of Patients with Giant Cell Arteritis and Polymyalgia Rheumatica: A Single-Center, Observational Long-Term Study
Elisheva Pokroy-Shapira¹, Ariela Dortort-Lazar^2,3 and Yair Molad^4,5, ¹Rheumatology Unit, Rabin Medical Center, Beilinson Hospital and Sackler Faculty of Medicine, Tel Aviv University, Petach Tikva, Israel, ²Rheumatology Unit, Beilinson hospital Rabin Medical Center, Petah Tikva, Israel, ³Sackler Faculty of Medicine Tel Aviv university, Tel Aviv, Israel, ⁴Rheumatology Unit, Rabin Medical Center, Beilinson Hospital, Petach Tikva, and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, ⁵Rheumatology Unit, Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israel
Background/Purpose: Patients with giant-cell arteritis (GCA) and polymyalgia rheumatica (PMR) are treated with high cumulative glucocorticoid (GC) dose during their disease course. We sought to…
Abstract Number: 507 • 2018 ACR/ARHP Annual Meeting
Echocardiographic Markers of Right Ventricle Dysfunction in Hispanic Patients with Rheumatoid Arthritis: A Case-Control Study
José R. Azpiri-López¹, Dionicio A. Galarza-Delgado², Iris J. Colunga-Pedraza³, Jose A. Davila-Jimenez⁴, Estefania E. Abundis-Marquez⁴, Andres H. Guillen-Lozoya⁴, Francisco J. Torres-Quintanilla⁴, Aldo Valdovinos-Bañuelos⁴, Ray Ramos-Cázares⁴, Raymundo Vera-Pineda⁴, Jesus A. Cardenas-de la Garza⁴, Rosa I. Arvizu-Rivera⁴ and Adrián Martínez-Moreno⁴, ¹Cardiology, Hospital Universitario, UANL, Monterrey, Mexico, ²Chief of Rheumatology, Hospital Universitario, UANL, Monterrey, Mexico, ³Rheumatology, Hospital Universitario, UANL, Monterrey, Mexico, ⁴Hospital Universitario, UANL, Monterrey, Mexico
Background/Purpose: Screening for cardiovascular (CV) disease in patients with rheumatoid arthritis (RA) remains controversial, however, there is agreement in considering echocardiography as the most immediate…
Abstract Number: 2778 • 2018 ACR/ARHP Annual Meeting
High Prevalence of Vascular Surgery and Autoimmune Comorbidity in Takayasu Arteritis
Tsuyoshi Shirai¹, Tomoyuki Muto², Yuko Shirota¹, Hiroshi Fujii¹, Tomonori Ishii³ and Hideo Harigae¹, ¹Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Japan, ²Tohoku University Graduate School of Medicine, Sendai, Japan, ³Clinical Research, Innovation and Education Center, Tohoku University Hospital, Sendai, Japan
Background/Purpose: Large vessel vasculitis (LVV) is the arteritis in aorta and its major branches, and classified into Takayasu arteritis (TAK) and giant cell arteritis (GCA).…
Abstract Number: 508 • 2018 ACR/ARHP Annual Meeting
Non-Invasive Evaluation of Left Atrial Pressure in Hispanic Patients with Rheumatoid Arthritis: A Case-Control Study
José R. Azpiri-López¹, Dionicio A. Galarza-Delgado², Iris J. Colunga-Pedraza³, Jose A. Davila-Jimenez⁴, Estefania E. Abundis-Marquez⁴, Andres H. Guillen-Lozoya⁴, Francisco J. Torres-Quintanilla⁴, Aldo Valdovinos-Bañuelos⁴, Ray Ramos-Cázares⁴, Raymundo Vera-Pineda⁴, Jesus A. Cardenas-de la Garza⁴, Rosa I. Arvizu-Rivera⁴ and Adrián Martínez-Moreno⁴, ¹Cardiology, Hospital Universitario, UANL, Monterrey, Mexico, ²Chief of Rheumatology, Hospital Universitario, UANL, Monterrey, Mexico, ³Rheumatology, Hospital Universitario, UANL, Monterrey, Mexico, ⁴Hospital Universitario, UANL, Monterrey, Mexico
Background/Purpose: In the last several years a higher prevalence of heart failure has been described in Rheumatoid arthritis (RA) patients, particularly heart failure with preserved…
Abstract Number: 512 • 2018 ACR/ARHP Annual Meeting
Incidence of First Cardiovascular Event in Spanish Patients with Chronic Inflammatory Rheumatic Diseases: Prospective Data from an Observational Multicentric Study
Maria Auxiliadora Martin¹, Santos Castañeda², Carlos González-Juanatey³, Fernando Sánchez-Alonso⁴, María Carmen García-Gómez⁵, R López-González⁶, Jesus Babio⁷, Antonio Juan-Mas⁸, María P Moreno-Gil⁹, Olga Sanchez-González¹⁰, Montserrat Romera¹¹, Jose A Pinto-Tasende¹², Jose A Piqueras¹³, Dolores Fábregas¹⁴, Javier Llorca¹⁵ and Miguel Angel González-Gay¹⁶, ¹Research Unit of Spanish Society of Rheumatology,, Madrid, Spain, ²Hospital Universitario La Princesa, IIS-Princesa, Madrid, Spain, ³Cardiology Division, Hospital Xeral-Calde, Lugo, Spain, ⁴Unidad de Investigación, Spanish Society of Rheumatology, Madrid, Spain, ⁵Rheumatology Division, Consorci Sanitari de Terrassa, Terrassa (Barcelona), Spain, ⁶Rheumatology, Complejo Hospitalario de Zamora. Spain, Zamora, Spain, ⁷Rhaumatology, H General de Cabueñes, Gijon, Spain, ⁸Division of Rheumatology, Hospital Son Llatzer, Palma de Mallorca, Spain, Spain, ⁹Division of Rheumatology, Hospital San Pedro de Alcántara, Cáceres, Spain, ¹⁰Division of Rheumatology, Hospital del Sureste, Madrid, Spain, ¹¹Division of Rheumatology, Hospital de Bellvitge, Barcelona, Spain, ¹²Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain, ¹³Division of Rheumatology, Hospital Universitario de Guadalajara, Guadalajara, Spain, ¹⁴Division of Rheumatology, Hospital de Barbastro, Huesca, Spain, ¹⁵Department of Epidemiology and Computational Biology, School of Medicine, University of Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), IDIVAL, Santander, Spain, Santander, Spain, ¹⁶School of Medicine, University of Cantabria, Santander, Spain, Santander, Spain
Background/Purpose: To determine the incidence and risk factors implicated in the development of first cardiovascular event (CVE) in patients with chronic inflammatory rheumatic diseases (CIRD)…
Abstract Number: 645 • 2018 ACR/ARHP Annual Meeting
Real World Secukinumab Study in Ankylosing Spondylitis and Psoriatic Arthritis – Comorbidities and Extraarticular Manifestations: Incidence and Status throughout a Non-Interventional Study in Germany
Uta Kiltz¹, Peter Kaestner², Holger Krauel², Ilka Schwarze³, Jan Brandt-Juergens⁴, Monika Maier-Peuschel⁵, Carolin Legeler⁵, Justyna Veit⁵ and Hans-Peter Tony⁶, ¹Rheumazentrum Ruhrgebiet, Herne, Germany, ²Rheumatology, Ambulantes Rheumazentrum, Erfurt, Germany, ³Praxis internistische Rheumatologie, Leipzig, Germany, ⁴Rheumatology, Rheumatologische Schwerpunktpraxis, Berlin, Germany, ⁵Novartis Pharma GmbH, Nürnberg, Germany, ⁶Rheumatology/Immunology, Medizinische Klinik II, Universitätsklinik, Würzburg, Germany
Background/Purpose: Patients with psoriatic arthritis (PsA) or ankylosing spondylitis (AS) may suffer from extraarticular (EA) manifestations (uveitis, psoriasis) and have higher rates of comorbidities like…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].